Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Behind the Clinical Trials for Non-Alcohol Fatty Liver Disease that Can Benefit 30% of Americans

The Impact Research Institute (IRI) is Waco, Texas’ resource for extending care options for NAFLD (non-alcohol fatty liver disease.) Nadege Gunn is IRI’s Medical Director and President. She joined Kevin Stevenson on I Don’t Care to discuss her and her team’s mission to treat NAFLD and other related diseases and conditions. Dr. Gunn is…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The Impact Research Institute (IRI) is Waco, Texas’ resource for extending care options for NAFLD (non-alcohol fatty liver disease.) Nadege Gunn is IRI’s Medical Director and President. She joined Kevin Stevenson on I Don’t Care to discuss her and her team’s mission to treat NAFLD and other related diseases and conditions.

Dr. Gunn is a Gastroenterologist and Hepatologist whose main passion is the liver. “The liver is an amazing organ,” Dr. Gunn said. “It’s the only organ in the body that you could cut in half, and it can grow back in full size in about three months. The work we do in transplantation and replacing the liver is quite amazing, so that’s why I chose the field in general.”

Dr. Gunn helped open IRI in July of 2021. Necessity created the decision to develop the center. While practicing clinical trials in Austin, Texas, Dr. Gunn saw many patients traveling from the Waco area to receive treatment options for NAFLD. With no scan or clinical trial options available to people in Waco and the surrounding area, Dr. Gunn recognized an opportunity to open a clinic to serve the growing needs.

Community outreach is critical to the clinic’s role in Waco, TX. When they identify candidates who may have NAFLD, they do a non-invasive scan at the center to determine if the candidate does have the disease. “If they do, then we invite them to maybe participate in a clinical trial because there are no treatments for fatty liver,” Dr. Gunn said.

For people wondering if they might have NAFLD, Dr. Gunn said the disease is often asymptomatic in the early stages. “It is when the disease is progressing, when it is starting to injure and harm the liver, that people might start firstly feeling fatigued,” Dr. Gunn said. “They might feel pain in the right upper quadrant of their abdomen and their belly.” Recognizing these warning signs and seeking a diagnosis is critical before full-on cirrhosis of the liver occurs.

More Like This Story:

Providing Real-Time Feedback for Virtual Health

Tearing Down the Barrier of Prior Authorization Through Automation

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Jessica Davison - Assistant Vice President of Strategy, Learning & Analytics, United Way of Greater Houston

Jessica Davison - Assistant Vice President of Strategy, Learning & Analytics, United Way of Greater Houston

Jessica Davison serves as the Assistant Vice President of Strategy, Learning & Analytics at United Way of Greater Houston. The article focuses on her strategic role and initiatives in analytics within the organization. The context is in the healthcare industry, with insights pertaining to Texas.

  • 01Jessica Davison is the Assistant Vice President of Strategy, Learning & Analytics at United Way of Greater Houston.
  • 02The article discusses strategic roles and analytics initiatives within healthcare.
  • 03The focus is on the healthcare industry in Texas.

Aug 25, 2026

Epic’s MyChart phishing wave is pushing patient-access teams to treat portal identity as a security perimeter

Epic’s MyChart phishing wave is pushing patient-access teams to treat portal identity as a security perimeter

Hospitals are alerting patients about phishing scams involving Epic’s MyChart, as these scams impersonate the patient portal to deceive users. The concern grows as CMS encourages healthcare innovation and interoperability. As a response, healthcare teams are treating portal identity as a vital security frontier.

  • 01Hospitals are experiencing phishing scams that mimic Epic’s MyChart portal.
  • 02The CMS continues to push for industry-led pledges toward healthcare interoperability.
  • 03Patient portal identity is being prioritized as a critical aspect of cybersecurity.

Aug 25, 2026

Adonis’ new CPO and first CRO signals AI RCM vendors are shifting from pilots to platform operating models

Adonis’ new CPO and first CRO signals AI RCM vendors are shifting from pilots to platform operating models

Adonis has appointed a new Chief Product Officer (CPO) and promoted its first Chief Revenue Officer (CRO), following a successful $40 million Series C funding round and a fourfold increase in revenue. This move underscores a shift among AI RCM vendors, like Adonis, from pilot projects to platform-based operating models. This transition is expected to result in more structured product roadmaps and a strong emphasis on value demonstration for health systems.

  • 01Adonis appointed a new CPO and promoted its first CRO.
  • 02The company achieved a $40 million Series C funding and a fourfold revenue increase.
  • 03AI RCM vendors are moving from pilot projects to platform operating models.

Aug 22, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512